SMi Reports: University of Cambridge speaker to brief on Artificial Intelligence for AI in Drug Discovery 2020 taking place in London in March 2020.
LONDON, UNITED KINGDOM, November 19, 2019 /EINPresswire.com/ — The upcoming inaugural AI in Drug Discovery conference is set to take place on 16th-17th March in London where number of key features have been confirmed for the highly anticipated event. AI in Drug Discovery 2020 will focus predominantly on AI machine learning technologies and its potential to reduce drug discovery costs by an estimated US$70 billion over the next decade, therefore leading the way to shorter, cheaper and more successful research and development.
Ahead of the two-day agenda, SMi has interviewed Andreas Bender, Lecturer for Molecular Informatics, University of Cambridge to discuss his view on the conference and what to expect from his presentation on ‘Artificial Intelligence in Drug Discovery – Opportunities and Pitfalls’. Dr Andreas Bender is a Reader for Molecular Informatics with the Centre for Molecular Science Informatics at the Department of Chemistry of the University of Cambridge, leading a group of about 22 postdocs, PhD and graduate students and academic visitors.
Snapshot of Andreas’ interview:
Can you tell us a little bit about your background in data-driven drug discovery informatics and your work in the field?
“I started working on cheminformatics in 1999, during the previous 'biotech boom', in a start up close to Berlin, did a PhD in the field in Cambridge. Afterwards I was happy to do an industrial postdoc with Novartis in Boston (where I learned about the complexity of biological high-content screening readouts), and for the last 12 years I have been a group leader in Leiden/The Netherlands, and Cambridge/UK. We work quite a lot with pharma and biotech companies and also started two companies ourselves – Healx and Pharmenable – so I would describe our work as quite applied.”
In your opinion, how does AI improve drug discovery and what are the potential areas where AI would be applicable?
“AI depends on data, and data depends on labels. Mostly you can only (relatively) clearly label early stage data – say, binding to a target (but even here the question is whether binding sites, functional effects, or kinetics are a difference that matters or not)…”
For the full interview and speaker line-up, the brochure is available to download online. Register at www.AI-indrugdiscovery.com/einpr3
Key features for this year’s conference include:
• Explore how lead scientists from 10 big pharma apply machine learning methods to fast-track de novo design, synthesis and ADME toxicity predictions in aid of drug discovery
• Listen to a panel discussion on the “AI paradigm shift – is it just a hype?” to find out what key opinion leaders think about the potential of AI for the future
• Discover the unique approach using the AI-led Benevolent Platform® deploys for re-imagining the full discovery pipeline using AI
• Deep dive into the latest case-studies from AstraZeneca exploring their strategies to integrating AI into drug design
An early bird saving of £400 is available for bookings made before 29th November 2019. Interested parties can secure their places at www.AI-indrugdiscovery.com/einpr3
AI in Drug Discovery Conference 2020
16th-17th March 2020
— ENDS –
For media enquiries, contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 or email@example.com
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
email us here
Source: EIN Presswire